Eyeworld

Experience Eyeworld's print publications online Digital.EyeWorld.org Archives EyeWorld Supplements EyeWorld Daily News ASCRS S AT U R DAY, M AY 16 , 2 0 2 0 | AS C R S V I R T U A L A N N U A L M E E T I N G DAILY NEWS HIGHLIGHTS ASCRS FOUNDATION UPDATE P. 6 FILM FESTIVAL PREVIEW P. 12 OPS WINNING IMAGES P. 28 way to help our members with the recovery process," he said. The meeting will feature more than 30 CME credits and more than 400 hours of content, and special sessions will highlight COVID-19-related content. Dr. Kim started by congrat- ulating and thanking Edward Holland, MD, chair of the ASCRS Program Committee, Steve Speares, ASCRS execu- tive director, ASCRS staff and leadership, industry sponsors, and participating faculty for by Ellen Stodola Editorial Co-Director T hough the ASCRS An- nual Meeting looks a bit different this year in its new, virtual for- mat, Terry Kim, MD, incoming president of ASCRS, said that it's a major step forward to ad- dress the current crisis, and he emphasized all the efforts that ASCRS is making to guide its members through these chal- lenging times. The Virtual Annual Meet- ing is an enormous initiative in terms of time and resources that ASCRS decided to under- take to address the COVID-19 crisis, Dr. Kim said. "We took this important step because we thought it would be the best their collaboration to make the very first Virtual Annual Meeting a reality. "We've never done a virtual meeting before, and due to having to cancel our Annual Meeting in Bos- ton fairly late, we didn't have much time to put this together. But thanks to the hard work and long hours put in by our Program Committee and ASCRS staff, we were able to produce a high-quality virtual Shifting gears to reflect on his year as president of ASCRS, Dr. Mamalis took a moment to pause and preface. "This terri- ble crisis in the whole country and what the entire profession is going through makes it diffi- cult to sit down and talk about what accomplishments have been done over the past year," Dr. Mamalis said. That said, he mentioned the rebranding of ASCRS that launched a year ago, making it clear what ASCRS does for its members and for surgeons. It's slogan—For surgeons. For you.—Dr. Mamalis said shows the commitment the society has for surgeons. "This is truly by Liz Hillman Editorial Co-Director N ick Mamalis, MD, outgoing president of ASCRS, shared his thoughts on the ASCRS Virtual Annual Meeting and his presidency as a whole. First, he gave "huge kudos" to the ASCRS staff and the Program Committee who took the full ASCRS Annual Meeting and distilled it into a 2-day virtual meeting in an extremely short period of time. "I'm very grateful that we were able to put togeth- er this meeting virtually," Dr. Mamalis said. "I am incredibly impressed at the amount of work everyone has been doing putting this together." Features he is excited for include the two-part "Turning the Lights Back On" session, which he said will be extremely timely for attendees. "The sessions on getting the practice going again, what are the steps to doing this … I think these are going to give invaluable information for people who are going through the process of restarting their practices," he said, adding later that these sessions come at a time when many states are be- ginning to loosen restrictions. He also noted the discus- sion with Scott Gottlieb, MD, former head of the FDA, who Dr. Mamalis said will likely offer valuable insights into this process. "The virtual meeting will also have the usual tremendous education that goes on at the ASCRS Annual Meeting," Dr. Mamalis said, mentioning that it even has a virtual exhibit hall for attendees to interact with industry representatives. continued on page 4 continued on page 3 Thoughts from outgoing ASCRS President Nick Mamalis, MD Incoming ASCRS President Terry Kim, MD, speaks about current situation and what ASCRS is doing to address this SUPPLEMENT TO EYEWORLD OCTOBER 2020 ASCRS Incorporating the ASCRS Preoperative OSD Algorithm into practice Platinum sponsors: Allergan, Kala Pharmaceuticals, Novartis, and Sight Sciences Bronze sponsors: Eyevance and Johnson & Johnson Vision Introduction to the ASCRS Preoperative OSD Algorithm continued on page 4 Christopher Starr, MD, is an Associate Professor of Ophthalmology, Director of the Refractive Surgery Service, and Director of Ophthalmic Education at Weill Cornell Medical College in New York, New York. He has financial interests with Alcon, Allergan, BlephEx, Bruder, Dompe, Essiri Labs, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Quidel, Sun Pharmaceutical, TearLab, and Verily. Kenneth Beckman, MD, is the Director of Corneal Surgery at Comprehensive Eyecare of Central Ohio and Clinical Assistant Professor of Ophthalmology at The Ohio State University in Columbus, Ohio. He has no relevant financial interests. Terry Kim, MD, is a Professor of Ophthalmology, Chief of the Cornea and External Disease Service, and Director of the Refractive Surgery Service at Duke University School of Medicine in Durham, North Carolina. He has financial interests with Aerie Pharmaceuticals, Alcon, Allergan, Avedro, Avellino Labs, Azura Ophthalmics, Bausch + Lomb, Carl Zeiss Meditec, CorneaGen, Dompe, Eyenovia, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, Ocular Therapeutix, Oculis, Omeros, Presbyopia Therapies, Sight Sciences, Simple Contacts, and Surface. Francis Mah, MD, is the Director of Corneal and External Disease and Co-Director of Refractive Surgery at the Scripps Clinic in La Jolla, California. He has financial interests with Allergan, Novartis, Bausch + Lomb, Kala Pharmaceuticals, TearLab, and Sight Sciences. Marjan Farid, MD, is a Clinical Professor of Ophthalmology and Director of Cornea, Cataract, and Refractive Surgery and the Ocular Surface Disease Program at the University of California, Irvine School of Medicine in Irvine, California. She has financial interests with Allergan, Bio-Tissue, CorneaGen, Dompe, Eyepoint, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, and Novartis. Preeya Gupta, MD, is an Associate Professor of Ophthalmology at Duke University School of Medicine in Durham, North Carolina. She has no relevant financial interests. T he last 15 years has been a new era for ocu- lar surface disease, but advances in diagnostics and treatment options have, according to recent ASCRS Clinical Surveys, left many ophthalmologists confused and overwhelmed, said Christopher Starr, MD. "The ASCRS Cornea Clin- ical Committee … decided to take this on as a very import- ant educational initiative, but first, why does ASCRS care so much about OSD?" Dr. Starr asked. There are several reasons: • Ocular surface disease (OSD) is present in the ma- jority of cataract patients, many of whom are asymp- tomatic. • OSD reduces the accuracy of preop and postop refractive measurements. • OSD reduces visual quality, quantity, and performance. • Anterior blepharitis may increase the risk of endoph- thalmitis. • Any eye surgery will worsen dry eye disease (DED)/OSD symptoms. In 2017, the ASCRS Clinical Survey found that 73% of respondents thought a practical, efficient preop diagnostic algorithm would be helpful. So that's what the Cornea Clinical Committee set out to create and provide to members. The goals were for the algorithm to be con- sensus- and evidence-based, integrated into the preop- erative surgery visit, reliant on techniques and objective testing to reduce chair time, and able to identify all visually significant subtypes of OSD, Dr. Starr said. The important steps of the algorithm created by the committee are as follows: Step 1. Noninvasive refractive preop measurements (ker- atometry, topography, optical biometry, aberrometry, etc.) Step 2. OSD screening battery (assessing for signs with tests—osmolarity and inflam- matory marker testing—and symptoms with the ASCRS SPEED II Preop Question- naire). If there is a positive screen, further OSD testing can be used if you've got it, Dr. Starr said. Step 3. Directed, quick exam to assess for visually signif- icant OSD (look, lift, push, pull, then stain) Step 4. OSD ruled in or out (if ruled in, determine visual significance) This supplement about the ASCRS Cornea Clinical Committee's algorithm for the preoperative diagnosis and treatment of ocular surface disorders is based off of discussion from a corporate-sponsored roundtable that took place at the 2019 ASCRS Annual Meeting. The supplement takes the discussion a step further with co-moderators of the roundtable, Christopher Starr, MD, and Francis Mah, MD, and the faculty, Kenneth Beckman, MD, Marjan Farid, MD, Terry Kim, MD, and Preeya Gupta, MD, giving new insights and practical applications for today's dry eye practice. Platinum sponsors: Allergan, Kala Pharmaceuticals, Novartis, and Sight Sciences | Bronze sponsors: Eyevance and Johnson & Johnson Vision Co-moderators Faculty tearcare.com

• Blank Page
• Blank Page (1)